Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom...
January 08 2020 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced that the United States Patent and
Trademark Office (USPTO) granted U.S. Patent No. 10,507,196 to
support Anavex’s leading drug candidate, ANAVEX®2-73 (blarcamesine)
for the treatment of neurodevelopmental disorders including Rett
syndrome, and multiple sclerosis.
Anavex’s newest patent is expected to remain in
force at least until 2037, not including any patent term
extensions. It covers methods of treatment for neurodevelopmental
disorders including Rett syndrome, autism spectrum disorder,
Angelman syndrome, and cerebral palsy, among others, and also
treatment for multiple sclerosis, using ANAVEX®2-73 (blarcamesine).
ANAVEX®2-73 (blarcamesine) is currently in several clinical studies
for Rett syndrome, including the U.S. Phase 2 Rett syndrome study1
and the AVATAR Rett syndrome study2, with the international
EXCELLENCE Rett syndrome study of ANAVEX®2-73 (blarcamesine) in
pediatric patients scheduled to initiate early 2020. The ‘196
patent adds important coverage for ANAVEX®2-73 (blarcamesine)
treatments for Rett syndrome and multiple sclerosis.
“We are extremely pleased with the continued
development of the patent portfolio for ANAVEX®2-73 (blarcamesine).
This new issuance of the U.S. patent continues to expand the
breadth and depth of our intellectual property and is another step
in the development of a robust patent portfolio relating to
ANAVEX®2-73 (blarcamesine),” said Christopher U. Missling, PhD,
President and Chief Executive Officer of Anavex.
ANAVEX®2-73 (blarcamesine) is an orally
available, small-molecule activator of the sigma-1 receptor which,
data suggest, is pivotal to restoring neural cell homeostasis and
promoting neuroplasticity.3
About and Rett Syndrome and Multiple
Sclerosis
Rett syndrome is a devastating, non-inherited
genetic post-natal progressive neurodevelopmental disorder that
occurs almost exclusively in girls and leads to severe impairments,
affecting nearly every aspect of the child’s life: their ability to
speak, walk, eat and easily breathe. The hallmark of Rett syndrome
is near constant repetitive hand movements while awake. The disease
is characterized by normal early growth and development (6 to 18
months) followed by a slowing of development, loss of purposeful
use of the hands, distinctive hand movements, autistic features,
slowed brain and head growth, ataxia, seizures and intellectual
disability.
Rett syndrome is caused by mutations in the
MECP2 gene and strikes all racial and ethnic groups. The disease
occurs worldwide in approximately one in every 10,000 to 15,000
live births. There is currently no cure for Rett syndrome.
Multiple sclerosis (MS) is a chronic
inflammatory-neurodegenerative disease of the central nervous
system (CNS), resulting in the accumulation of irreversible
disabilities such as muscle weakness, visual disturbances and other
neurological impairments. MS is the most common autoimmune disorder
of the CNS, and worldwide, ~2.3 million people are affected. Most
people experience their first symptoms of MS between the ages of 20
and 40. Currently there is no cure for MS and many medications have
serious side effects and some carry significant risks.4 There is
still a huge unmet need for agents directly interacting with the
central nervous system: Regeneration, axonal protection, neuronal
protection and remyelination.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
recently completed a successful Phase 2a clinical trial for
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally
available drug candidate that restores cellular homeostasis by
targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy. The Michael J. Fox
Foundation for Parkinson’s Research previously awarded Anavex a
research grant, which fully funded a preclinical study to develop
ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s
disease. ANAVEX®3-71, which targets sigma-1 and muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease-modifying activity against the major hallmarks of
Alzheimer’s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies. In preclinical
trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial
dysfunction and neuroinflammation.
Further information is available at
www.anavex.com. You can also connect with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:
Email:
ir@anavex.com
__________________________
1 ClinicalTrials.gov Identifier: NCT037589242 ClinicalTrials.gov
Identifier: NCT039414443 Advances in Experimental Medicine and
Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease
and as Therapeutic Targets.4
https://www.ninds.nih.gov/Disorders/All-Disorders/Multiple-Sclerosis-Information-Page
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2023 to Sep 2024